

Michael D Jain

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6122888/publications.pdf>

Version: 2024-02-01

59
papers

2,402
citations

304743

22
h-index

223800

46
g-index

61
all docs

61
docs citations

61
times ranked

2468
citing authors

#	ARTICLE	IF	CITATIONS
1	Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. <i>Journal of Clinical Oncology</i> , 2020, 38, 3119-3128.	1.6	481
2	Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T). <i>Journal of the American College of Cardiology</i> , 2019, 74, 3099-3108.	2.8	225
3	CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. <i>Blood</i> , 2021, 138, 2499-2513.	1.4	160
4	Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 978-986.	3.5	141
5	Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. <i>Blood</i> , 2021, 137, 2621-2633.	1.4	137
6	High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 3268-3276.	5.2	134
7	Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 387-405.	4.9	124
8	Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 1012-1021.	0.8	105
9	Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience. <i>Blood</i> , 2018, 132, 91-91.	1.4	81
10	High-resolution mapping of the Gli3 mutation Extra-toes1 reveals a 51.5-kb deletion. <i>Mammalian Genome</i> , 2002, 13, 58-61.	2.2	80
11	Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3034-3043.	1.6	76
12	Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 2886-2898.	5.2	59
13	The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. , 2022, 10, e004475.		50
14	Concise Review: Emerging Principles from the Clinical Application of Chimeric Antigen Receptor T Cell Therapies for B Cell Malignancies. <i>Stem Cells</i> , 2018, 36, 36-44.	3.2	48
15	Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel. <i>Blood</i> , 2021, 137, 1832-1835.	1.4	48
16	Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel. <i>Clinical Cancer Research</i> , 2020, 26, 4823-4831.	7.0	47
17	Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin's lymphoma. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1007-1017.	2.0	45
18	Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy. <i>British Journal of Haematology</i> , 2019, 187, e35-e38.	2.5	35

#	ARTICLE	IF	CITATIONS
19	Seek and You Shall Findâ€”But Then What Do You Do? Cold Agglutinins in Cardiopulmonary Bypass and a Single-Center Experience With Cold Agglutinin Screening Before Cardiac Surgery. <i>Transfusion Medicine Reviews</i> , 2013, 27, 65-73.	2.0	32
20	Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. <i>Blood</i> , 2022, 140, 491-503.	1.4	32
21	Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 1145-1154.	0.8	29
22	Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. <i>Blood Cancer Discovery</i> , 2022, 3, 385-393.	5.0	29
23	A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. <i>Blood Advances</i> , 2021, 5, 1154-1163.	5.2	26
24	Cell Biology of the Endoplasmic Reticulum and the Golgi Apparatus through Proteomics. <i>Cold Spring Harbor Perspectives in Biology</i> , 2013, 5, a015073-a015073.	5.5	24
25	Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 4086-4090.	5.2	22
26	Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 305.e1-305.e9.	1.2	14
27	Cytokine release syndrome and neurologic toxicities associated with chimeric antigen receptor T-cell therapy: A comprehensive review of emerging grading models. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 13, 1-6.	0.9	12
28	Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphomaâ€”type postâ€”transplant lymphoproliferative disorder. <i>British Journal of Haematology</i> , 2020, 189, 97-105.	2.5	12
29	SubID, a non-median dichotomization tool for heterogeneous populations, reveals the pan-cancer significance of INPP4B and its regulation by EVI1 in AML. <i>PLoS ONE</i> , 2018, 13, e0191510.	2.5	9
30	Radiation Therapy As a Bridging Strategy for Refractory Diffuse Large B Cell Lymphoma Patients Awaiting CAR T Manufacturing of Axicabtagene Ciloleucel. <i>Blood</i> , 2018, 132, 4220-4220.	1.4	7
31	CSF1R Is Associated with Poor Overall Survival in AML and Mediates Supportive Interactions Between AML and Stromal Cells in the AML Microenvironment. <i>Blood</i> , 2016, 128, 2666-2666.	1.4	7
32	Quality of life in caregivers of patients receiving chimeric antigen receptor Tâ€”cell therapy. <i>Psycho-Oncology</i> , 2021, 30, 1294-1301.	2.3	6
33	Prediction of CAR T-Related Toxicities in R/R DLBCL Patients Treated with Axicabtagene Ciloleucel Using Point of Care Cytokine Measurements. <i>Blood</i> , 2018, 132, 95-95.	1.4	6
34	Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 753-759.	0.4	6
35	Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL. <i>Blood Advances</i> , 2022, 6, 3970-3973.	5.2	6
36	Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma. <i>Drugs</i> , 2017, 77, 1645-1655.	10.9	5

#	ARTICLE	IF	CITATIONS
37	Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 242.e1-242.e6.	1.2	5
38	A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease. <i>Blood Advances</i> , 2022, 6, 259-269.	5.2	5
39	Workplace-Based Assessment of Internal Medicine Resident Diagnostic Accuracy. <i>Journal of Graduate Medical Education</i> , 2014, 6, 532-535.	1.3	4
40	Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 768.e1-768.e6.	1.2	4
41	Preliminary outcomes reported from three randomized controlled trials of CD19 CAR-T cell therapies in large B cell lymphoma. <i>Molecular Therapy</i> , 2022, 30, 14-16.	8.2	4
42	A Phase II Study of Sirolimus-Based Calcineurin Inhibitor-Free Gvhd Prophylaxis after Peripheral Blood Haploidentical Transplantation with Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S58.	2.0	3
43	Management Across Settings: An Ambulatory and Community Perspective for Patients Undergoing CAR T-Cell Therapy in Multiple Care Settings. , 2019, 23, 27-34.		3
44	Imagining the cell therapist: Future CAR T cell monitoring and intervention strategies to improve patient outcomes. <i>EJHaem</i> , 2022, 3, 46-53.	1.0	3
45	Methemoglobinemia from curing salt. <i>Cmaj</i> , 2013, 185, E771-E771.	2.0	2
46	Hypofibrinogenemia in Patients Receiving CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Large B Cell Lymphoma: A Single Institution Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S257-S258.	2.0	2
47	Identification of Early Predictive Markers of Toxicity and Efficacy in Patients with DLBCL Treated with Axicabtagene Ciloleucel. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S245-S246.	2.0	2
48	Obinutuzumab as bridging therapy for successful manufacturing of axicabtagene ciloleucel for transformed follicular lymphoma with circulating cells. <i>American Journal of Hematology</i> , 2019, 94, E245-E247.	4.1	1
49	Incidence and Management of Venous Thrombo-Embolism (VTE) Associated with CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy: A Single Institution Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S265.	2.0	1
50	The ASH Practice Improvement Module in Non-Hodgkin Lymphoma: Assessing the Feasibility, Reliability and Usefulness of a New Quality Improvement Tool. <i>Blood</i> , 2014, 124, 2651-2651.	1.4	1
51	Tumor infiltrating lymphocytes predict survival in solid organ transplant recipients with monomorphic post-transplant lymphoproliferative disorders. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.4	1
52	Phase II Multicenter Study of Ofatumumab in Combination with Glucocorticoids As a Primary Therapy for Chronic Graft Versus Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S182-S183.	2.0	0
53	Incidence and Management of Effusions during CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Receptor Therapy in B-Cell Lymphoma: A Single Institution Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S265-S266.	2.0	0
54	Seeing the light: CAR T cell targeting of lambda-restricted B cell lymphomas. <i>Clinical Cancer Research</i> , 2021, 27, clincanres.1450.2021.	7.0	0

#	ARTICLE	IF	CITATIONS
55	Seek and You Shall Find “ but Then What Do You Do? Cold Agglutinins in Cardiopulmonary Bypass, and a Single Center Experience with Cold Agglutinin Screening Before Cardiac Surgery. Blood, 2012, 120, 4372-4372.	1.4	0
56	A Single-Center Retrospective Study of 140 Patients with Post-Transplant Lymphoproliferative Disorder Following Solid Organ Transplantation. Blood, 2016, 128, 4227-4227.	1.4	0
57	INPP4B is a Biomarker of Poor Prognosis in AML Which is Associated with EVI1 Overexpression and a LSC Signature. Blood, 2016, 128, 3929-3929.	1.4	0
58	Advances in aggressive lymphoma from the 2018 American Society of Clinical Oncology annual meeting: commentary. Clinical Advances in Hematology and Oncology, 2018, 16 Suppl 14, 20-23.	0.3	0
59	Transverse myelitis after anti-CD19 directed CAR T cell therapy for relapsed large B cell lymphoma. EJHaem, 2022, 3, 223-227.	1.0	0